Routine deworming

PreclinicalSmall molecule

LLondon School of Hygiene and Tropical Medicine

Routine deworming is one of 12 small molecule programs targeting MPR. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MPRCompleted

MPRPreclinical

Completed

Competition

Competitive Landscape

17 competitors in MPR

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

2 2

Lioresal

Novartis

Phase 3

1 3

Glucophage

EMD Serono

Phase 3

2 4

Cytosar

Teva

Phase 2

1 5

Rapamycin

MMaastricht Radiation Oncology

Phase 3

1 6

Glycerin

CCalm Water Therapeutics LLC

Phase 3

1 7

Ampyra

MMerz North America, Inc.

Phase 1

1 8

Fragmin

Pfizer

Preclinical

1 9

Agenerase

GGlaxo Dba Glaxosmithkline

Preclinical

3 10

ECT-001-CB

EExCellThera inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MPR1 trial

Evaluating Impact of Improved Floors on Health

Completed·LLondon School of Hygiene and Tropical Medicine·N/A·NCT05914363·2,200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Routine deworming. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Routine deworming compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Routine deworming. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — London School of Hygiene and Tropical Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLondon School of Hygiene and Tropical Medicine

Routine deworming

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MPR1 trial

References

Drug Info

Quick Facts

Related News